血清YKL-40和VILIP 1水平与痴呆症患者的大脑体积之间的相关性
Didem Tezen1, Esra Koçhan Kızılkılıç2, Ayşegül Akkan Suzan1
1Department of Neurology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey.
Geriatrics & gerontology international
|February 3, 2025
概括
阿尔茨海默病与大脑体积减少有关. 新的研究表明神经炎症标志物YKL-40和视类蛋白1 (VILIP-1) 和特定的大脑区域之间的相关性.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 神经成像是一种神经成像.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 情节性记忆障碍是阿尔茨海默病的一个关键症状.
- 神经元损伤和神经炎症与阿尔茨海默病的发病有关.
- 维西宁样蛋白1 (VILIP-1) 和YKL-40是AD的有希望的血清/血生物标志物.
研究的目的:
- 为了研究血清VILIP-1和YKL-40水平与大脑体积变化在可能的阿尔茨海默病之间的关系.
- 探索这些生物标志物在早期阿尔茨海默病诊断和治疗中的潜力.
主要方法:
- 血清VILIP-1和YKL-40水平测量了33名可能患有AD的患者和23名健康对照.
- 磁共振成像 (MRI) 用于大脑结构的体积测量.
- 在阿尔茨海默病患者的生物标志物水平和大脑体积之间进行了相关性分析.
主要成果:
- 与对照人群相比,可能患有AD的患者在多个大脑区域 (包括海马体,杏仁体,皮质和白质) 显示出明显较低的体积.
- YKL-40水平与左后带皮带体积负相关.
- 维利普-1水平与左桃体体积负相关.
结论:
- 阿尔茨海默病与边缘结构,皮质和白质的显著缩有关.
- 该研究确定了YKL-40和VILIP-1水平与左后带状皮质和左桃体之间的特定相关性.
- 这些发现有助于理解神经炎症标志物与AD中的结构性大脑变化之间的联系.
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
01:29Hepatic Encephalopathy
53
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
53